Bortezomib
DrugBank ID: DB00188
Summary
| Metric | Value |
|---|---|
| Total Predictions | 51 |
| KG+DL (Dual Validated) | 2 |
| DL Only | 48 |
| KG Only | 1 |
Predictions
| Indication | Score | Source |
|---|---|---|
| vertebral anomalies and variable endocrine and T-cell dysfunction | 0.9610 | DL |
| ganglioneuroblastoma (disease) | 0.9601 | DL |
| retroperitoneal neoplasm | 0.9564 | DL |
| neuroblastoma | 0.9511 | DL |
| mantle cell lymphoma | 0.8513 | DL |
| Hodgkins lymphoma | 0.8509 | DL |
| myeloid leukemia | 0.8377 | DL |
| lymphoma, non-Hodgkin, familial | 0.8359 | DL |
| lymphosarcoma | 0.8187 | KG+DL |
| colon adenocarcinoma | 0.7912 | DL |
| lymph node cancer | 0.7796 | DL |
| dermatofibrosarcoma protuberans | 0.7701 | DL |
| B-cell neoplasm | 0.7699 | KG+DL |
| primary organ-specific lymphoma | 0.7260 | DL |
| chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 0.7117 | DL |
| pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 0.7117 | DL |
| acute lymphoblastic/lymphocytic leukemia | 0.6996 | DL |
| Ewing sarcoma | 0.6972 | DL |
| primary cutaneous T-cell non-Hodgkin lymphoma | 0.6875 | DL |
| AIDS-related primary central nervous system lymphoma | 0.6794 | DL |
| composite lymphoma | 0.6794 | DL |
| nasal cavity lymphoma | 0.6794 | DL |
| ovarian lymphoma | 0.6794 | DL |
| progressive transformation of germinal centers | 0.6794 | DL |
| lymphoid neoplasm | 0.6787 | DL |
| breast lymphoma | 0.6720 | DL |
| lymphoma | 0.6718 | DL |
| methotrexate-associated lymphoproliferative disorders | 0.6697 | DL |
| lymphoid hemopathy | 0.6680 | DL |
| B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma | 0.6625 | DL |
| eye lymphoma | 0.6595 | DL |
| ureteral lymphoma | 0.6585 | DL |
| tracheal lymphoma | 0.6580 | DL |
| obsolete Hodgkin's granuloma | 0.6491 | DL |
| retroperitoneal lymphoma | 0.6473 | DL |
| interdigitating dendritic cell sarcoma | 0.6452 | DL |
| primary cutaneous B-cell lymphoma | 0.6358 | DL |
| blast phase chronic myelogenous leukemia, BCR-ABL1 positive | 0.6326 | DL |
| bladder lymphoma | 0.6317 | DL |
| subcutaneous panniculitis-like T-cell lymphoma | 0.6317 | DL |
| uterine corpus sarcoma | 0.6259 | DL |
| classic Hodgkin lymphoma | 0.6241 | DL |
| nodular lymphocyte predominant Hodgkin lymphoma | 0.6197 | DL |
| thymic epithelial neoplasm | 0.6156 | DL |
| Hodgkin's paragranuloma | 0.6121 | DL |
| Hodgkin's lymphoma, lymphocytic depletion | 0.6113 | DL |
| neonatal jaundice | 0.6043 | DL |
| reticulum cell sarcoma | 0.6026 | DL |
| chronic myelogenous leukemia, BCR-ABL1 positive | 0.5916 | DL |
| classic Hodgkin lymphoma, lymphocyte-depleted type | 0.5878 | DL |
Showing top 50 of 51 predictions.
External Links
Disclaimer
Predictions are for research purposes only and do not constitute medical advice.
Predictions are for research purposes only and do not constitute medical advice.